Source: PR Newswire

Press Release: CSL Behring : CSL Behring Announces Availability of Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe

/PRNewswire/ -- CSL Behring, a business unit of global biotechnology leader CSL, today announced the availability of a 10g prefilled syringe for Hizentra®...

Read full article »

CSL Behring's Competitors | CSL Behring's News | CSL Behring's Financials

Followers on Owler

2,816

Est. Annual Revenue

$10-50B

Est. Employees

10-50K

Managing Director & CEO

Paul Roger Perreault

CEO Approval Rating

93/100

CSL Behring is a Pennsylvania-based biopharmaceutical company that develops protein-based therapies for the treatment of bleeding disorders and pulmonary disease.